Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Olivier Bylicki
No relevant relationships to disclose
Celine Ferlay
No relevant relationships to disclose
Christos Chouaid
Honoraria - Amgen; Boehringer Ingelheim; GlaxoSmithKline; Lilly; Novartis; Roche
Research Funding - Amgen; Lilly; Roche
Armelle Lavolle
No relevant relationships to disclose
Fabrice Barlesi
Consultant or Advisory Role - Roche
Honoraria - Lilly; Roche
Research Funding - Lilly
Radj Gervais
No relevant relationships to disclose
Virginie Westeel
Consultant or Advisory Role - Lilly; Roche
Honoraria - Boehringer Ingelheim; Lilly; Roche
Research Funding - Roche
Other Remuneration - AstraZeneca; Lilly; Roche
Jacky Crequit
No relevant relationships to disclose
Romain Corre
Honoraria - Lilly
Research Funding - Lilly
Alain Vergnenegre
Consultant or Advisory Role - Lilly; Roche
Gerard Zalcman
Consultant or Advisory Role - Lilly; Roche
Honoraria - Lilly; Roche
Isabelle Monnet
No relevant relationships to disclose
Herve Le Caer
Honoraria - Lilly; Roche
Pierre Fournel
Research Funding - Lilly
Pauline Linard
No relevant relationships to disclose
David Perol
Honoraria - Lilly; Roche
Maurice Perol
Consultant or Advisory Role - Lilly; Pfizer; Roche
Honoraria - Lilly; Roche
Research Funding - Lilly; Roche